GARDP, Debiopharm to collaborate on new gonorrhea antibiotic
13 January 2026
13 January 2026
The Global Antibiotic Research & Development Partnership (GARDP) and Swiss biopharmaceutical company Debiopharm today announced a collaboration on a novel antibiotic targeting gonorrhea.
Under the collaboration and license agreement, GARDP and Debiopharm will jointly develop Debio1453, a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria gonorrhoeae and has shown potent clinical activity against the bacterium in preclinical studies, including multidrug-resistant strains.